Skip to main content

Table 3 IGFBP3 mRNA levels for patients with breast cancer and with BBD, stratified by menopausal status

From: IGFBP3mRNA expression in benign and malignant breast tumors

Status

Disease

Tumor tissue

Adjacent tissue

  

No. of patients

IGFBP3 mRNA level

No. of patients

IGFBP3 mRNA level

Premenopausal

BBD

88

231.6 (147.8, 488.0)

54

178.9 (104.6, 300.3)

 

Breast cancer

91

146.2 (85.2, 289.2)

41

199.4 (156.6, 274.1)

 

p a

 

<0.001

 

0.472

 

BBD

    
 

   Non-proliferative lesions

53

185.4 (109.6, 279.4)

31

139.2 (100.2, 243.2)

 

   Proliferative lesions

35

353.1 (197.9, 709.3)

23

219.1 (141.8, 394.3)

 

p a

 

0.006

 

0.055

 

Breast cancer (by stage)

    
 

   0 and I

23

125.0 (102.7, 169.0)

16

203.1 (85.4, 263.9)

 

   IIa

36

196.5 (86.7, 337.6)

16

200.9 (126.8, 344.1)

 

   IIb, III & IV

32

139.1 (78.9, 301.8)

9

199.4 (165.1, 235.0)

 

p for trend testa

 

0.775

 

0.740

Postmenopausal

BBD

7

314.2 (183.9, 528.5)

5

201.8 (73.9, 390.0)

 

Breast cancer

50

121.8 (96.3, 223.2)

21

208.2 (167.1, 362.8)

 

p a

 

0.006

 

0.184

 

BBD

    
 

   Non-proliferative lesions

4

249.1 (119.4, 421.3)

3

201.8 (29.5, 390.0)

 

   Proliferative lesions

3

472.6 (274.5, 1500.8)

2

239.5 (73.9, 405.1)

 

p a

 

0.157

 

0.763

 

Breast cancer (by stage)

    
 

   0 and I

9

126.7 (116.8, 220.8)

5

221.0 (155.2, 262.6)

 

   IIa

26

112.1 (96.3, 202.2)

10

206.9 (179.0, 382.1)

 

   IIb, III & IV

15

141.1 (72.7, 351.8)

6

243.9 (159.0, 727.6)

 

p for trend testa

 

0.670

 

0.308

  1. Results for IGFBP3 mRNA levels are shown as median (25th, 75th centile). BBD, benign breast disease; IGFBP3, gene encoding insulin-like growth factor binding protein 3. aAdjusted for age.